Summit Therapeutics reports insufficient funds to sustain operations for the next 12 months, raising going-concern risks.
Summit Therapeutics disclosed that its current cash, cash equivalents, and short-term investments are inadequate to fund operations for at least the next year. The biotech firm issued the warning after Thursday’s market close, signaling potential financial distress.
The company did not provide further details on contingency plans or additional funding sources. Prior financial disclosures had not flagged an imminent liquidity crisis, though cash burn rates have been a focus for investors.
Shares fell approximately 5% in after-hours trading following the announcement.